Virginia Ruth Sanzone, VP and General Counsel of ICU Medical Inc/DE (NASDAQ:ICUI), filed a Form 4 on September 3, 2026, disclosing the sale of 4,856 shares of common stock across four transactions executed that same day under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Total shares sold: 4,856 shares of ICU Medical common stock disposed of on September 3, 2026.
  • Price ranges: The four sale tranches carried weighted average prices of $167.667, $168.4352, $169.5255, and $171.515, with individual transaction prices ranging from $167.20 to $171.69.
  • 10b5-1 plan: All sales were made pursuant to a Rule 10b5-1 trading plan adopted by Sanzone on June 8, 2026.
  • Remaining ownership: Following the reported transactions, Sanzone directly beneficially owned 14,604 shares of common stock.
  • Transaction code: All four transactions are coded "S" (sale) and are reported as direct ownership disposals.

Sanzone's Four-Tranche Sale of ICU Medical Common Stock

According to the filing, Virginia Ruth Sanzone, serving as VP and General Counsel at ICU Medical Inc/DE, disposed of shares in four separate tranches on September 3, 2026. The first tranche involved 2,202 shares at a weighted average price of $167.667, with individual prices ranging from $167.20 to $168.145. The second tranche covered 1,238 shares at a weighted average of $168.4352, with prices ranging from $168.21 to $169.15. Following those sales, Sanzone held 16,020 shares directly.

The filing discloses that the third tranche consisted of 724 shares sold at a weighted average price of $169.5255, with prices ranging from $169.5 to $169.665, reducing the beneficial ownership to 15,296 shares. The fourth and final tranche was 692 shares at a weighted average price of $171.515, with prices ranging from $170.775 to $171.69, bringing the post-transaction direct beneficial ownership to 14,604 shares. All prices reported in the filing are described as weighted average prices, and the reporting person undertakes to provide full per-share detail upon request to ICU Medical, any security holder, or SEC staff.

The filing indicates that the box for a Rule 10b5-1(c) plan is checked, and the explanation of responses states that "the restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026." The form was signed by Paula Darbyshire as Attorney-in-Fact for Virginia Sanzone and filed on September 3, 2026. No derivative security transactions were reported.

What Was Disclosed

The filing reports the sale of 4,856 total shares of ICU Medical common stock by VP General Counsel Virginia Ruth Sanzone on September 3, 2026, conducted under a pre-adopted 10b5-1 plan, leaving her with 14,604 directly held shares.